{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T20:13:35Z","timestamp":1785615215083,"version":"3.56.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.euros.2025.12.014","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:30:42Z","timestamp":1767198642000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis"],"prefix":"10.1016","volume":"84","author":[{"given":"Yixian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2025.12.014_b0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.12.014_b0010","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euros.2025.12.014_b0015","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2025.12.014_b0020","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.euros.2025.12.014_b0025","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"Mateo","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.euros.2025.12.014_b0030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.12.014_b0035","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.12.014_b0045","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41391-018-0121-2","article-title":"Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry","volume":"22","author":"Francini","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euros.2025.12.014_b0050","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.euros.2025.12.014_b0055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.12.014_b0065","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.euo.2024.02.005","article-title":"Olaparib combined with abiraterone versus olaparib monotherapy for patients with metastatic castration-resistant prostate cancer progressing after abiraterone and harboring DNA damage repair deficiency: a multicenter real-world study","volume":"7","author":"Xie","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0070","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0075","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.21.02947","article-title":"Randomized trial of olaparib with or without cediranib for metastatic castration-resistant prostate cancer: the results from National Cancer Institute 9984","volume":"41","author":"Kim","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0080","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.12.014_b0085","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0090","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0095","unstructured":"U.S. Food and Drug Administration. FDA D.I.S.C.O. Burst Edition. FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer. FDA; 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-lynparza-olaparib-abiraterone-and-prednisone-brca-mutated."},{"key":"10.1016\/j.euros.2025.12.014_b0100","unstructured":"U.S. Food and Drug Administration. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. FDA; 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer."},{"key":"10.1016\/j.euros.2025.12.014_b0105","unstructured":"European Medicines Agency (EMA). Lynparza. EMA; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/lynparza-epar-medicine-overview_en.pdf."},{"key":"10.1016\/j.euros.2025.12.014_b0110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euros.2025.12.014_b0115","unstructured":"National Heart, Lung, and Blood Institute. Study Quality Assessment Tools. National Institutes of Health; 2021. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"10.1016\/j.euros.2025.12.014_b0120","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.23.01868","article-title":"FDA approval summary: olaparib in combination with abiraterone for treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0125","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial","volume":"42","author":"Mateo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0130","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","article-title":"Abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (BRCAAway)","volume":"30","author":"Hussain","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euros.2025.12.014_b0135","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.euros.2025.12.014_b0140","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1158\/2159-8290.CD-13-0679","article-title":"Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer","volume":"3","author":"Bartek","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euros.2025.12.014_b0145","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euros.2025.12.014_b0150","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euros.2025.12.014_b0155","doi-asserted-by":"crossref","first-page":"14573","DOI":"10.1073\/pnas.1908547116","article-title":"Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function","volume":"116","author":"Gui","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.euros.2025.12.014_b0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.euros.2025.12.014_b0165","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nbt.2121","article-title":"Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors","volume":"30","author":"Wahlberg","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.euros.2025.12.014_b0170","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1200\/JCO.2017.75.7310","article-title":"Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012","volume":"36","author":"Hussain","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102359","article-title":"PARP inhibitors for metastatic castration-resistant prostate cancer: biological rationale and current evidence","volume":"104","author":"Bie\u0144kowski","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euros.2025.12.014_b0180","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.12.014_b0185","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euros.2025.12.014_b0190","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aam7479","article-title":"Androgen receptor inhibitor-induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","volume":"10","author":"Li","year":"2017","journal-title":"Sci Signal"},{"key":"10.1016\/j.euros.2025.12.014_b0195","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S1470-2045(22)00498-3","article-title":"Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial","volume":"23","author":"Saad","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0200","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.12.014_b0205","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12032-022-01648-5","article-title":"Olaparib for Chinese metastatic castration-resistant prostate cancer: a real-world study of efficacy and gene predictive analysis","volume":"39","author":"Dong","year":"2022","journal-title":"Med Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0210","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0215","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1007\/s12325-023-02634-7","article-title":"Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix vs leuprolide: subgroup analysis from HERO study in advanced prostate cancer","volume":"40","author":"Shore","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.euros.2025.12.014_b0220","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.euo.2023.07.013","article-title":"Combining PARP inhibitors and androgen receptor signalling inhibitors in metastatic prostate cancer: a quantitative synthesis and meta-analysis","volume":"7","author":"Messina","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2025.12.014_b0225","article-title":"Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.euros.2025.12.014_b0230","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euo.2023.09.001","article-title":"Poly (ADP-ribose) polymerase inhibitors have comparable efficacy with platinum chemotherapy in patients with BRCA-positive metastatic castration-resistant prostate cancer. A systematic review and meta-analysis","volume":"7","author":"Fazekas","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325024929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325024929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:04:55Z","timestamp":1771866295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168325024929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":46,"alternative-id":["S2666168325024929"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2025.12.014","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2025.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}